EG436008 Inhibitors
EG436008 inhibitors represent a class of small molecules characterized by their selective ability to bind and inhibit a specific target protein, which is typically involved in a particular cellular process or signaling pathway. The specificity of these inhibitors arises from their unique structural features, which allow them to interact precisely with their target, often through hydrogen bonds, hydrophobic interactions, or coordination with metal ions. The molecular structure of EG436008 inhibitors commonly consists of aromatic ring systems, heterocycles, or substituted alkyl chains, which contribute to their ability to fit into the binding pocket of the target protein. This binding can alter the conformation or function of the target, resulting in the modulation of its biological activity. The exact chemical composition of these inhibitors can vary, but they are designed to achieve high specificity and affinity for their intended target.
The activity of EG436008 inhibitors is not only dependent on their binding to the protein but also on their stability, solubility, and capacity to permeate biological membranes. These properties influence their behavior in biological systems, including their bioavailability and distribution within a cell or organism. Structural optimization of EG436008 inhibitors is often performed to enhance their selectivity and improve their binding affinity while reducing off-target effects. Modifications to the core structure, side chains, or functional groups are typical strategies used to fine-tune their interactions with the target protein. Furthermore, the potency and inhibitory capacity of these molecules are often evaluated using biochemical assays that measure how effectively the inhibitor blocks its target protein's function, such as through enzyme activity inhibition or binding assays. These molecular and biochemical characteristics collectively define EG436008 inhibitors as a sophisticated class of small molecules designed to interact precisely with specific protein targets, providing valuable tools for studying and modulating cellular pathways at the molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | $104.00 $315.00 | ||
Fenretinide, a synthetic retinoid, inhibits Sdr42e2 indirectly by modulating the retinoic acid signaling pathway. Acting as a retinoid X receptor (RXR) agonist, Fenretinide influences RXR-dependent transcription, impacting Sdr42e2 expression and function within cellular contexts where retinoid signaling is operative. | ||||||
Clomiphene Citrate | 50-41-9 | sc-205636 sc-205636A | 1 g 5 g | $84.00 $176.00 | 1 | |
Clomifene indirectly inhibits Sdr42e2 by modulating estrogen receptor signaling. As a selective estrogen receptor modulator (SERM), Clomifene alters estrogen receptor activity, leading to downstream effects that impact Sdr42e2 expression and function within estrogen-responsive cellular environments. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Flufenamic Acid indirectly inhibits Sdr42e2 by influencing the cyclooxygenase (COX) pathway. Acting as a non-selective COX inhibitor, Flufenamic Acid disrupts prostaglandin synthesis, affecting downstream signaling events that impact Sdr42e2 expression and function within cellular contexts sensitive to COX-mediated signaling. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $92.00 | 1 | |
Anastrozole, an aromatase inhibitor, indirectly influences Sdr42e2 by modulating estrogen synthesis. By inhibiting aromatase, Anastrozole reduces estrogen levels, leading to downstream effects that impact Sdr42e2 expression and function within cellular environments where estrogen plays a regulatory role. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 is a selective peroxisome proliferator-activated receptor-gamma (PPARγ) antagonist, indirectly inhibiting Sdr42e2 through PPARγ modulation. By interfering with PPARγ activity, GW9662 influences downstream transcriptional events that impact Sdr42e2 expression and function within cellular contexts where PPARγ-mediated signaling is relevant. | ||||||
Triclosan | 3380-34-5 | sc-220326 sc-220326A | 10 g 100 g | $141.00 $408.00 | ||
Triclosan indirectly inhibits Sdr42e2 by affecting cellular redox status. As an antibacterial agent, Triclosan disrupts redox homeostasis, leading to downstream effects that impact Sdr42e2 expression and function within cellular environments sensitive to oxidative stress-mediated signaling. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin indirectly inhibits Sdr42e2 by modulating the mevalonate pathway. Acting as a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, Simvastatin influences downstream isoprenoid biosynthesis, affecting Sdr42e2 expression and function within cellular contexts where mevalonate pathway-mediated signaling is operative. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine indirectly inhibits Sdr42e2 by influencing calcium signaling. As a calcium channel blocker, Nifedipine disrupts intracellular calcium dynamics, leading to downstream effects that impact Sdr42e2 expression and function within cellular environments where calcium-dependent signaling is operational. | ||||||
Bisphenol A | 80-05-7 | sc-391751 sc-391751A | 100 mg 10 g | $300.00 $490.00 | 5 | |
Bisphenol A indirectly inhibits Sdr42e2 by interfering with estrogen receptor signaling. As an endocrine-disrupting chemical, Bisphenol A alters estrogen receptor activity, leading to downstream effects that impact Sdr42e2 expression and function within estrogen-responsive cellular environments. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $42.00 $146.00 | 27 | |
Bicalutamide, an androgen receptor antagonist, indirectly influences Sdr42e2 by modulating androgen receptor signaling. By inhibiting androgen receptor activity, Bicalutamide affects downstream transcriptional events that impact Sdr42e2 expression and function within androgen-responsive cellular environments. | ||||||